The developed HPLC method provides a sensitive, selective, and precise approach for measuring therapeutic serum levels of propranolol without interference from common drugs or metabolites.
May support HPLC-based TDM for propranolol; leaves open prospective validation in patient cohorts.
A high pressure liquid chromatographic method (HPLC) has been developed to measure therapeutic levels of the beta-blocker and antiarrhythmic drug propranolol in serum. A reverse phase CN column was used with an acetate counter-ion in an aqueous/methanol mobile phase to separate propranolol from an internal standard (protriptyline) and potential interferences such as procainamide and quinidine after a basic ether extraction. Fluorometric detection at 215 nm excitation and 326 nm emission provided sensitivity and selectivity. The linear range was found to be 10–350 ng/mL and was beyond the usual therapeutic ranges. The between-run precision was demonstrated to be 3–7% (CV). The method was compared with a less specific non-chromatographic fluorometric method using patient samples. The results were often higher using the non-chromatographic method. No interferences were found among the over 50 drugs and 5 propranolol metabolites tested. The relationship of dose to peak serum propranolol was examined in 20 patients.
No takes yet. Share an insight, caveat, or question.
Simón et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: